The Perirenal Fat Thickness Was Associated with Nonalcoholic Fatty Liver Disease in Patients with Type 2 Diabetes Mellitus

References

• Younossi ZM, Koenig AB, Abdelatif D, Fazel Y, Henry L, Wymer M. Global epidemiology of nonalcoholic fatty liver disease-meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology. 2016;64(1):73–84. doi:10.1002/hep.28431
   PubMed Web of Science ®Google Scholar
• Lu ZY, Shao Z, Li YL, Wulasihan M, Chen XH. Prevalence of and risk factors for non-alcoholic fatty liver disease in a Chinese population: an 8-year follow-up study. World J Gastroenterol. 2016;22(13):3663–3669. doi:10.3748/wjg.v22.i13.3663
   PubMed Web of Science ®Google Scholar
• Lee C, Kim J, Jung Y. Potential therapeutic application of estrogen in gender disparity of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis. Cells. 2019;8(10):1259. doi:10.3390/cells8101259
   Web of Science ®Google Scholar
• Hou XH, Zhu YX, Lu HJ, et al. Non-alcoholic fatty liver disease’s prevalence and impact on alanine aminotransferase associated with metabolic syndrome in the Chinese. J Gastroenterol Hepatol. 2011;26(4):722–730. doi:10.1111/j.1440-1746.2010.06509.x
   Web of Science ®Google Scholar
• Jump DB, Lytle KA, Depner CM, Tripathy S. Omega-3 polyunsaturated fatty acids as a treatment strategy for nonalcoholic fatty liver disease. Pharmacol Ther. 2018;181:108–125. doi:10.1016/j.pharmthera.2017.07.007
   PubMed Web of Science ®Google Scholar
• Stefan N, Haring HU, Cusi K. Non-alcoholic fatty liver disease: causes, diagnosis, cardiometabolic consequences, and treatment strategies. Lancet Diabetes Endocrinol. 2019;7(4):313–324. doi:10.1016/S2213-8587(18)30154-2
   PubMed Web of Science ®Google Scholar
• Polyzos SA, Kountouras J, Mantzoros CS. Obesity and nonalcoholic fatty liver disease: from pathophysiology to therapeutics. Metabolism. 2019;92:82–97. doi:10.1016/j.metabol.2018.11.014
   PubMed Web of Science ®Google Scholar
• Mantovani A, Byrne CD, Bonora E, Targher G. Nonalcoholic fatty liver disease and risk of incident type 2 diabetes: a meta-analysis. Diabetes Care. 2018;41(2):372–382. doi:10.2337/dc17-1902
   PubMed Web of Science ®Google Scholar
• Younossi ZM, Golabi P, de Avila L, et al. The global epidemiology of NAFLD and NASH in patients with type 2 diabetes: a systematic review and meta-analysis. J Hepatol. 2019;71(4):793–801. doi:10.1016/j.jhep.2019.06.021
   PubMed Web of Science ®Google Scholar
• Dai W, Ye L, Liu A, et al. Prevalence of nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus: a meta-analysis. Medicine. 2017;96(39):e8179. doi:10.1097/MD.0000000000008179
   PubMed Web of Science ®Google Scholar
• Bril F, Cusi K. Management of nonalcoholic fatty liver disease in patients with type 2 diabetes: a call to action. Diabetes Care. 2017;40(3):419–430. doi:10.2337/dc16-1787
   PubMed Web of Science ®Google Scholar
• Xing J, Guan X, Zhang Q, Chen S, Wu S, Sun X. Triglycerides mediate body mass index and nonalcoholic fatty liver disease: a population-based study. Obes Facts. 2021;14(2):190–196. doi:10.1159/000514848
   Web of Science ®Google Scholar
• Lin YC, Chang PF, Liu K, Chang MH, Ni YH. Predictors for incidence and remission of nonalcoholic fatty liver disease in obese children and adolescents. J Formos Med Assoc. 2022;121(1 Pt 1):36–42. doi:10.1016/j.jfma.2021.01.004
   Web of Science ®Google Scholar
• Zhou X, Li Y, Zhang X, et al. Independent markers of nonalcoholic fatty liver disease in a gentrifying population-based Chinese cohort. Diabetes Metab Res Rev. 2019;35(5):e3156. doi:10.1002/dmrr.3156
   PubMed Web of Science ®Google Scholar
• Kim D, Chung GE, Kwak MS, et al. Body fat distribution and risk of incident and regressed nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol. 2016;14(1):132–138 e134. doi:10.1016/j.cgh.2015.07.024
   PubMed Web of Science ®Google Scholar
• Chiyanika C, Wong VW, Wong GL, et al. Implications of abdominal adipose tissue distribution on nonalcoholic fatty liver disease and metabolic syndrome: a Chinese general population study. Clin Transl Gastroenterol. 2021;12(2):e00300. doi:10.14309/ctg.0000000000000300
   Web of Science ®Google Scholar
• Ye Q, Zou B, Yeo YH, et al. Global prevalence, incidence, and outcomes of non-obese or lean non-alcoholic fatty liver disease: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2020;5(8):739–752. doi:10.1016/S2468-1253(20)30077-7
   PubMed Web of Science ®Google Scholar
• Kechagias S, Nasr P, Blomdahl J, Ekstedt M. Established and emerging factors affecting the progression of nonalcoholic fatty liver disease. Metabolism. 2020;111S:154183. doi:10.1016/j.metabol.2020.154183
   PubMed Web of Science ®Google Scholar
• Kim D, Kim WR. Nonobese fatty liver disease. Clin Gastroenterol Hepatol. 2017;15(4):474–485. doi:10.1016/j.cgh.2016.08.028
   PubMed Web of Science ®Google Scholar
• Jung CH, Rhee EJ, Kwon H, Chang Y, Ryu S, Lee WY. Visceral-to-subcutaneous abdominal fat ratio is associated with nonalcoholic fatty liver disease and liver fibrosis. Endocrinol Metab. 2020;35(1):165–176. doi:10.3803/EnM.2020.35.1.165
   Web of Science ®Google Scholar
• Item F, Konrad D. Visceral fat and metabolic inflammation: the portal theory revisited. Obes Rev. 2012;13(Suppl 2):30–39. doi:10.1111/j.1467-789X.2012.01035.x
   PubMed Web of Science ®Google Scholar
• Liu BX, Sun W, Kong XQ. Perirenal fat: a unique fat pad and potential target for cardiovascular disease. Angiology. 2019;70(7):584–593. doi:10.1177/0003319718799967
   PubMed Web of Science ®Google Scholar
• Raptopoulos V, Touliopoulos P, Lei QF, Vrachliotis TG, Marks SC Jr. Medial border of the perirenal space: CT and anatomic correlation. Radiology. 1997;205(3):777–784. doi:10.1148/radiology.205.3.9393535
   Web of Science ®Google Scholar
• Shen FC, Cheng BC, Chen JF. Peri-renal fat thickness is positively associated with the urine albumin excretion rate in patients with type 2 diabetes. Obes Res Clin Pract. 2020;14(4):345–349. doi:10.1016/j.orcp.2020.06.006
   Web of Science ®Google Scholar
• Fang Y, Xu Y, Yang Y, Liu C, Zhao D, Ke J. The relationship between perirenal fat thickness and reduced glomerular filtration rate in patients with type 2 diabetes. J Diabetes Res. 2020;2020:6076145. doi:10.1155/2020/6076145
   PubMed Web of Science ®Google Scholar
• Bassols J, Martinez-Calcerrada JM, Prats-Puig A, et al. Perirenal fat is related to carotid intima-media thickness in children. Int J Obes. 2018;42(4):641–647. doi:10.1038/ijo.2017.236
   Web of Science ®Google Scholar
• Kawasaki S, Hasegawa O, Satoh S, Numata K, Terauchi Y. Sonographic assessment of fatty liver infiltration using the measurement of para- and perirenal fat thickness. J Clin Ultrasound. 2010;38(9):470–474. doi:10.1002/jcu.20736
   Web of Science ®Google Scholar
• Alberti KG, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med. 1998;15(7):539–553. doi:10.1002/(SICI)1096-9136(199807)15:7<539::AID-DIA668>3.0.CO;2-S
   PubMed Web of Science ®Google Scholar
• Gao X, Fan JG; Study Group of L, Metabolism CSoE. Diagnosis and management of non-alcoholic fatty liver disease and related metabolic disorders: consensus statement from the Study Group of Liver and Metabolism, Chinese Society of Endocrinology. J Diabetes. 2013;5(4):406–415. doi:10.1111/1753-0407.12056
   PubMed Web of Science ®Google Scholar
• European Association for the Study of the L, European Association for the Study of D, European Association for the Study of O. EASL-EASD-EASO clinical practice guidelines for the management of non-alcoholic fatty liver disease. J Hepatol. 2016;64(6):1388–1402. doi:10.1016/j.jhep.2015.11.004
   PubMed Web of Science ®Google Scholar
• Shen X, Jin C, Wu Y, et al. Prospective study of perceived dietary salt intake and the risk of non-alcoholic fatty liver disease. J Hum Nutr Diet. 2019;32(6):802–809. doi:10.1111/jhn.12674
   Web of Science ®Google Scholar
• Angulo P, Hui JM, Marchesini G, et al. The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD. Hepatology. 2007;45(4):846–854. doi:10.1002/hep.21496
   PubMed Web of Science ®Google Scholar
• Kaswala DH, Lai M, Afdhal NH. Fibrosis assessment in Nonalcoholic Fatty Liver Disease (NAFLD) in 2016. Dig Dis Sci. 2016;61(5):1356–1364. doi:10.1007/s10620-016-4079-4
   PubMed Web of Science ®Google Scholar
• Vitturi N, Soattin M, De stefano F, et al. Ultrasound, anthropometry and bioimpedance: a comparison in predicting fat deposition in non-alcoholic fatty liver disease. Eat Weight Disord. 2015;20(2):241–247. doi:10.1007/s40519-014-0146-z
   Web of Science ®Google Scholar
• Shao C, Ye J, Li F, Feng S, Wang W, Zhong B. Different predictors of steatosis and fibrosis severity among lean, overweight and obese patients with nonalcoholic fatty liver disease. Dig Liver Dis. 2019;51(10):1392–1399. doi:10.1016/j.dld.2019.02.019
   Google Scholar
• Mansour A, Mohajeri-Tehrani MR, Samadi M, et al. Risk factors for non-alcoholic fatty liver disease-associated hepatic fibrosis in type 2 diabetes patients. Acta Diabetol. 2019;56(11):1199–1207. doi:10.1007/s00592-019-01374-x
   PubMed Web of Science ®Google Scholar
• Kim Y, Chang Y, Cho YK, Ahn J, Shin H, Ryu S. Obesity and weight gain are associated with progression of fibrosis in patients with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol. 2019;17(3):543–550 e542. doi:10.1016/j.cgh.2018.07.006
   Web of Science ®Google Scholar
• Kim D, Kim W, Joo SK, et al. Predictors of nonalcoholic steatohepatitis and significant fibrosis in non-obese nonalcoholic fatty liver disease. Liver Int. 2019;39(2):332–341. doi:10.1111/liv.13983
   Web of Science ®Google Scholar
• Sookoian S, Pirola CJ. Systematic review with meta-analysis: the significance of histological disease severity in lean patients with nonalcoholic fatty liver disease. Aliment Pharmacol Ther. 2018;47(1):16–25. doi:10.1111/apt.14401
   PubMed Web of Science ®Google Scholar
• Lu FB, Hu ED, Xu LM, et al. The relationship between obesity and the severity of non-alcoholic fatty liver disease: systematic review and meta-analysis. Expert Rev Gastroenterol Hepatol. 2018;12(5):491–502. doi:10.1080/17474124.2018.1460202
   PubMed Web of Science ®Google Scholar
• Cusi K. Role of obesity and lipotoxicity in the development of nonalcoholic steatohepatitis: pathophysiology and clinical implications. Gastroenterology. 2012;142(4):711–725 e716. doi:10.1053/j.gastro.2012.02.003
   PubMed Web of Science ®Google Scholar
• Manco M, Bedogni G, Marcellini M, et al. Waist circumference correlates with liver fibrosis in children with non-alcoholic steatohepatitis. Gut. 2008;57(9):1283–1287. doi:10.1136/gut.2007.142919
   Web of Science ®Google Scholar
• Du Plessis J, van Pelt J, Korf H, et al. Association of adipose tissue inflammation with histologic severity of nonalcoholic fatty liver disease. Gastroenterology. 2015;149(3):635–648.e14. doi:10.1053/j.gastro.2015.05.044
   PubMed Web of Science ®Google Scholar
• van der Poorten D, Milner KL, Hui J, et al. Visceral fat: a key mediator of steatohepatitis in metabolic liver disease. Hepatology. 2008;48(2):449–457. doi:10.1002/hep.22350
   PubMed Web of Science ®Google Scholar
• Snel M, Jonker JT, Schoones J, et al. Ectopic fat and insulin resistance: pathophysiology and effect of diet and lifestyle interventions. Int J Endocrinol. 2012;2012:983814. doi:10.1155/2012/983814
   PubMed Web of Science ®Google Scholar
• Hui JM, Sud A, Farrell GC, et al. Insulin resistance is associated with chronic hepatitis C virus infection and fibrosis progression [corrected]. Gastroenterology. 2003;125(6):1695–1704. doi:10.1053/j.gastro.2003.08.032
   PubMed Web of Science ®Google Scholar
• Neuschwander-Tetri BA. Hepatic lipotoxicity and the pathogenesis of nonalcoholic steatohepatitis: the central role of nontriglyceride fatty acid metabolites. Hepatology. 2010;52(2):774–788. doi:10.1002/hep.23719
   PubMed Web of Science ®Google Scholar
• Milic S, Lulic D, Stimac D. Non-alcoholic fatty liver disease and obesity: biochemical, metabolic and clinical presentations. World J Gastroenterol. 2014;20(28):9330–9337. doi:10.3748/wjg.v20.i28.9330
   PubMed Web of Science ®Google Scholar
• Angulo P, Machado MV, Diehl AM. Fibrosis in nonalcoholic Fatty liver disease: mechanisms and clinical implications. Semin Liver Dis. 2015;35(2):132–145. doi:10.1055/s-0035-1550065
   Web of Science ®Google Scholar
• Huh JH, Kim KJ, Kim SU, et al. Obesity is more closely related with hepatic steatosis and fibrosis measured by transient elastography than metabolic health status. Metabolism. 2017;66:23–31. doi:10.1016/j.metabol.2016.10.003
   PubMed Web of Science ®Google Scholar
• Moon YA. The SCAP/SREBP pathway: a mediator of hepatic steatosis. Endocrinol Metab. 2017;32(1):6–10. doi:10.3803/EnM.2017.32.1.6
   Web of Science ®Google Scholar
• Boutari C, Perakakis N, Mantzoros CS. Association of adipokines with development and progression of nonalcoholic fatty liver disease. Endocrinol Metab. 2018;33(1):33–43. doi:10.3803/EnM.2018.33.1.33
   Web of Science ®Google Scholar